<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000480.pub2" GROUP_ID="STROKE" ID="303199072717105335" MERGED_FROM="" MODIFIED="2008-09-03 16:00:04 +0200" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-03 14:54:54 +0100" NOTES_MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-09-03 16:00:04 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Vinpocetine for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2008-09-03 16:00:04 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7186" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dániel</FIRST_NAME><LAST_NAME>Bereczki</LAST_NAME><SUFFIX>MD, PhD, DSc</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>bereczki@neur.sote.hu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Semmelweis University</ORGANISATION><ADDRESS_1>Balassa u. 6.</ADDRESS_1><CITY>Budapest</CITY><ZIP>H-1083</ZIP><COUNTRY CODE="HU">Hungary</COUNTRY><PHONE_1>+36 1 210 0337</PHONE_1><FAX_1>+36 1 210 1368</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-03 16:00:04 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7186" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dániel</FIRST_NAME><LAST_NAME>Bereczki</LAST_NAME><SUFFIX>MD, PhD, DSc</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>bereczki@neur.sote.hu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Semmelweis University</ORGANISATION><ADDRESS_1>Balassa u. 6.</ADDRESS_1><CITY>Budapest</CITY><ZIP>H-1083</ZIP><COUNTRY CODE="HU">Hungary</COUNTRY><PHONE_1>+36 1 210 0337</PHONE_1><FAX_1>+36 1 210 1368</FAX_1></ADDRESS></PERSON><PERSON ID="16467" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>István</FIRST_NAME><LAST_NAME>Fekete</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>fekete@dote.hu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University of Debrecen, Health Science and Medical Center</ORGANISATION><ADDRESS_1>Móricz Zs. krt. 22</ADDRESS_1><CITY>Debrecen</CITY><ZIP>H-4032</ZIP><COUNTRY CODE="HU">Hungary</COUNTRY><PHONE_1>+36 52 415 176</PHONE_1><FAX_1>+36 52 453 590</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-03 14:46:51 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="16" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="2" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-03 14:48:28 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-03 14:48:32 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-03 14:48:32 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="16" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>The 'Background' section has been updated to include recent research results. One additional study was identified that fulfilled the inclusion criteria (Feigin 2001). This small, single-blind randomised study included 30 patients; including it did not change the conclusions regarding the primary outcome measure (death and dependency).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University Medical School of Debrecen</NAME>
<COUNTRY CODE="HU">Hungary</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Grant No. ETT 178/2006, Ministry of Health</NAME>
<COUNTRY CODE="HU">Hungary</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-03 14:54:54 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY>
<TITLE>Vinpocetine for acute ischaemic stroke</TITLE>
<SUMMARY_BODY>
<P>Stroke is a life-threatening event in which part of the brain does not receive enough oxygen, usually because of a blood clot blocking an artery in the brain. Stroke is the third leading cause of death and is an important cause of long-term disability. Vinpocetine is a synthetic drug that is based on a herbal vinca alkaloid; it may protect nerves by increasing blood flow in the brain. Randomised placebo-controlled studies have reported improved cognitive function after vinpocetine administration to people with long-term brain circulation disorders. Vinpocetine is also used in people with stroke, mostly in East European and Asian countries. This review set out to determine whether giving vinpocetine in the first two weeks after onset of stroke symptoms decreased the number of people who died or became dependent on others for care and activities of daily living. The review authors searched the medical literature but found only two controlled studies including 70 participants. There was no significant difference in the rate of death and dependency at one and three months between the treatment and placebo groups. No adverse effects were reported. This review did not provide any evidence that vinpocetine benefits patients with acute ischaemic stroke.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Vasoactive and neuroprotective drugs such as vinpocetine are used to treat stroke in some countries.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effect of vinpocetine in acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group Trials Register (last searched February 2007), MEDLINE (1966 to February 2007) and Scopus (1960 to February 2007). We also searched the Internet Stroke Center Stroke Trials Registry, Google Scholar, the science-specific search engine Scirus and Wanfang Data, the leading information provider in China. We contacted researchers in the field and four pharmaceutical companies that manufacture vinpocetine. Searches were complete to February 2007.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Unconfounded randomised trials of vinpocetine compared with placebo, or any other reference treatment, in people with acute ischaemic stroke. We included trials if treatment started no later than 14 days after stroke onset.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently applied the inclusion criteria. One review author extracted the data, which was then checked by the second review author. We assessed trial quality. The primary outcome measure was death or dependency.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included two trials, involving a total of 70 participants. Data for 63 participants were reported in the two trials combined. The rate of death or dependency did not differ between the treatment and placebo groups at one and three months. The 95% confidence intervals for the outcome measures were wide and included the possibility of both significant benefit and significant harm. No adverse effects were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to evaluate the effect of vinpocetine on survival or dependency in patients with acute ischaemic stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-03 14:54:54 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Stroke is the third leading cause of death and is probably the most important cause of long-term disability in most western nations (<LINK REF="REF-Bonita-1992" TYPE="REFERENCE">Bonita 1992</LINK>). Although stroke mortality has declined in most countries of Western Europe this was not the case in Eastern European countries between 1970 and 1985; the yearly increase in stroke mortality was the highest in Hungary among 27 countries studied (<LINK REF="REF-Bonita-1990" TYPE="REFERENCE">Bonita 1990</LINK>). After a maximum in 1994, mortality has been declining in Eastern European countries as well (<LINK REF="REF-Kesteloot-2006" TYPE="REFERENCE">Kesteloot 2006</LINK>). For secondary stroke prevention recommendations for antiplatelet therapy and indications for carotid endarterectomy have been established (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>; <LINK REF="REF-Moore-1995" TYPE="REFERENCE">Moore 1995</LINK>; <LINK REF="REF-Sacco-2006" TYPE="REFERENCE">Sacco 2006</LINK>). In acute stroke recombinant tissue plasminogen activator (rtPA) (<LINK REF="REF-Wardlaw-2003" TYPE="REFERENCE">Wardlaw 2003</LINK>) and aspirin (<LINK REF="REF-Sandercock-2003" TYPE="REFERENCE">Sandercock 2003</LINK>) are effective but there is no other medical or surgical therapy that can be uniformly recommended for routine use in each patient with acute ischaemic stroke, and all neuroprotectants tested to date failed in clinical trials (<LINK REF="REF-Broderick-2002" TYPE="REFERENCE">Broderick 2002</LINK>; <LINK REF="REF-EUSI-2003" TYPE="REFERENCE">EUSI 2003</LINK>; <LINK REF="REF-Adams-2007" TYPE="REFERENCE">Adams 2007</LINK>). </P>
<P>Vinpocetine, a vasoactive vinca alkaloid that is a synthetic derivative of apovincamine, has been listed among neuroprotectants even in recent reviews (<LINK REF="REF-Rose-2002" TYPE="REFERENCE">Rose 2002</LINK>; <LINK REF="REF-O_x0027_Collins-2006" TYPE="REFERENCE">O'Collins 2006</LINK>). The neuroprotectant activity of vinpocetine is attributed to three molecular mechanisms of action of the substance. First, the neuroprotectant as well as the anticonvulsant effect of vinpocetine may be due to the blockage of sodium channels (<LINK REF="REF-Lakics-1995" TYPE="REFERENCE">Lakics 1995</LINK>; <LINK REF="REF-Moln_x00e1_r-1995" TYPE="REFERENCE">Molnár 1995</LINK>; <LINK REF="REF-Tretter-1998" TYPE="REFERENCE">Tretter 1998</LINK>; <LINK REF="REF-B_x00f6_n_x00f6_czk-2000" TYPE="REFERENCE">Bönöczk 2000</LINK>; <LINK REF="REF-Zhou-2003" TYPE="REFERENCE">Zhou 2003</LINK>; <LINK REF="REF-Sitges-2007" TYPE="REFERENCE">Sitges 2007</LINK>). Second, vinpocetine reduces calcium-influx into neuronal cells (<LINK REF="REF-Zelles-2001" TYPE="REFERENCE">Zelles 2001</LINK>). Third, the antioxidant activity of vinpocetine may also contribute to its neuroprotectant effect (<LINK REF="REF-Pereira-2000" TYPE="REFERENCE">Pereira 2000</LINK>; <LINK REF="REF-Santos-2000" TYPE="REFERENCE">Santos 2000</LINK>; <LINK REF="REF-Horvath-2002" TYPE="REFERENCE">Horvath 2002</LINK>; <LINK REF="REF-Mendoza-2007" TYPE="REFERENCE">Mendoza 2007</LINK>).</P>
<P>In animal experiments vinpocetine was reported to protect against cell death in cell cultures of rat cerebral cortex (<LINK REF="REF-Erd_x00f6_-1990" TYPE="REFERENCE">Erdö 1990</LINK>) and in striatal slices of rat brain (<LINK REF="REF-Kiss-1991" TYPE="REFERENCE">Kiss 1991</LINK>), and had cytoprotective activity and prevented apoptosis in hypoxia (<LINK REF="REF-Gabryel-2002" TYPE="REFERENCE">Gabryel 2002</LINK>). Vinpocetine had calcium antagonist activity in in vitro models of cerebral ischaemia (<LINK REF="REF-Lamar-1988" TYPE="REFERENCE">Lamar 1988</LINK>), increased the neuroprotective effect of adenosine in hypoxia in cell cultures (<LINK REF="REF-Krieglstein-1991" TYPE="REFERENCE">Krieglstein 1991</LINK>), decreased neuronal cell loss in a rat model of forebrain ischaemia (<LINK REF="REF-Sauer-1988" TYPE="REFERENCE">Sauer 1988</LINK>), and prevented post ischaemic increase in glucose utilisation and decrease in local blood flow (<LINK REF="REF-Rischke-1990b" TYPE="REFERENCE">Rischke 1990b</LINK>) in the hippocampus of rats. Vinpocetine was reported to decrease the size of cerebral infarction after middle cerebral artery occlusion in rats (<LINK REF="REF-Rischke-1990a" TYPE="REFERENCE">Rischke 1990a</LINK>) and in mice (<LINK REF="REF-Backhauss-1992" TYPE="REFERENCE">Backhauss 1992</LINK>). Vinpocetine was found to be effective in restoring neuronal plasticity after toxic injury (<LINK REF="REF-Medina-2006" TYPE="REFERENCE">Medina 2006</LINK>).</P>
<P>In human observational studies vinpocetine was reported to increase cerebral blood flow in previously ischaemic cerebral regions (<LINK REF="REF-Tamaki-1985" TYPE="REFERENCE">Tamaki 1985</LINK>), to decrease platelet aggregability (<LINK REF="REF-Itoh-1982" TYPE="REFERENCE">Itoh 1982</LINK>) in patients after transient ischaemic attack (TIA) or stroke, and to increase erythrocyte deformability in patients after ischaemic stroke (<LINK REF="REF-Hayakawa-1992" TYPE="REFERENCE">Hayakawa 1992</LINK>). Based on 11C-labelled vinpocetine positron emission tomographic studies, vinpocetine distributes mainly in the thalamus, the basal ganglia, and the visual cortex, both after oral and intravenous administration (<LINK REF="REF-Gulyas-2002a" TYPE="REFERENCE">Gulyas 2002a</LINK>; <LINK REF="REF-Gulyas-2002b" TYPE="REFERENCE">Gulyas 2002b</LINK>). </P>
<P>Application of vasoactive and neuroprotective drugs is one of the numerous methods used in some countries for the treatment of patients with acute ischaemic stroke. Open and blinded randomised placebo controlled studies reported improving blood flow and glucose metabolism after vinpocetine administration in perifocal regions (<LINK REF="REF-Szakall-1998" TYPE="REFERENCE">Szakall 1998</LINK>; <LINK REF="REF-Szilagyi-2005" TYPE="REFERENCE">Szilagyi 2005</LINK>) in patients after ischaemic stroke. In a double-blind placebo-controlled study vinpocetine was reported to increase cerebral perfusion and oxygen extraction (<LINK REF="REF-B_x00f6_n_x00f6_czk-2002" TYPE="REFERENCE">Bönöczk 2002</LINK>). Cognitive functions (scored on the mini mental state questionnaire and clinical global impression) were reported to improve after vinpocetine administration in chronic cerebrovascular disorders (<LINK REF="STD-Manconi-1986" TYPE="STUDY">Manconi 1986</LINK>; <LINK REF="REF-Balestreri-1987" TYPE="REFERENCE">Balestreri 1987</LINK>). A randomised, placebo-controlled, double-blind clinical trial found that vinpocetine prevented the worsening of attention in patients with multiple cerebral infarcts (<LINK REF="REF-Kemeny-2005" TYPE="REFERENCE">Kemeny 2005</LINK>). </P>
<P>Based on the results of pharmacological studies and data from animal experiments, vinpocetine was recommended for use (<LINK REF="REF-Kov_x00e1_cs-1985" TYPE="REFERENCE">Kovács 1985</LINK>) and has been administered to patients with stroke in several countries in Europe (e.g. Hungary, Poland, Germany, Russia) and in Asia (e.g. China, Japan).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review is to determine if vinpocetine treatment decreases the rate of early (within one month) and late (between three and six months) case fatality and dependency if administered within two weeks of ischaemic stroke onset.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-03 14:54:29 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We attempted to identify all published and unpublished truly randomised unconfounded clinical trials that compared the effect of vinpocetine with control for acute ischaemic stroke when treatment starts no later than 14 days after stroke onset. We considered randomised comparisons between vinpocetine and other standard treatments confounded, whereas a comparison of vinpocetine plus standard treatment versus standard treatment alone was acceptable.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>As the aim of this review is the evaluation of vinpocetine therapy in the acute phase of ischaemic stroke, we did not consider studies where participants were randomised after 14 days of stroke onset for inclusion in the review. Distinction between ischaemic and haemorrhagic stroke cannot be made unless results of computerised tomography (CT) scans are reported for all participants in the trials (examination of the cerebrospinal fluid cannot be accepted as a reliable method to exclude haemorrhage). </P>
<P>It is possible that vinpocetine has considerable effects on platelet and other haemostatic functions (<LINK REF="REF-Itoh-1982" TYPE="REFERENCE">Itoh 1982</LINK>), so vinpocetine might have different effects in ischaemic and haemorrhagic strokes. Therefore, we planned two analyses for presumed and confirmed ischaemic stroke separately. In the first analysis we would include studies where CT was not routinely performed and participants with suspected cerebral haemorrhage were excluded on clinical signs or cerebrospinal fluid examination, and only in few cases by CT. We planned to do a second set of analyses on studies including participants with confirmed ischaemic stroke, therefore restricted to trials where all participants had a CT scan; that is, haemorrhage was reliably excluded before randomisation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We planned to include trials of either oral or intravenous treatment schedules in the review. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome of interest is death or dependency. The number of participants who are dead or dependent was estimated in the treatment groups at one month after stroke onset and at a later time point between three and six months. We planned to evaluate dependency in activities of daily living, in preference to a disability score (such as the Barthel scale), in the treatment groups. Secondary outcome measures were death at one and at three months, and adverse events. As far as safety parameters are concerned, we attempted to determine the rate of fatal and non-fatal cerebral haemorrhages, the rate of pulmonary embolism, and the frequency of other fatal and non-fatal adverse events in each treatment group.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-03 14:50:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in February 2007. In addition, we searched MEDLINE (1966 to February 2007) using the following search statement to include all known manufacturer code names and registered trade names for vinpocetine.</P>
<P>(vinpocetin$ or TCV-3B or RGH-4405 or CAS 42971-09-5 or Eusenium or Cavinton or Calan or Intelectol).tw.</P>
<P>We also searched Scopus (http://www.scopus.com) (1960 to February 2007), the Internet Stroke Center Stroke Trials Registry (www.strokecenter.org), Google Scholar (http://scholar.google.com), the science-specific search engine Scirus (http://www.scirus.com) and Wanfang Data (www.wanfangdata.com), the leading information provider in China; we used the search terms 'vinpocetine and (stroke or cerebral)'. Searches were complete to February 2007.</P>
<P>In an effort to identify further published, unpublished and ongoing trials we contacted researchers who had participated in vinpocetine trials and four pharmaceutical companies that manufacture vinpocetine (Gedeon Richter Ltd, Budapest, Hungary; Takeda Chemical Industries Ltd, Osaka, Japan; Covex SA, Madrid, Spain; and Thiemann Arzneimittel, Waltrop, Germany). (Last contact February 2007). The main manufacturer of the drug (Gedeon Richter Ltd, Hungary) supplied English transcripts of papers on possibly relevant trials printed in Japanese. Dr L Mihálka, a neurologist, evaluated Russian and Ukrainian papers to decide if they were randomised trials or not. We used the English language abstracts of Chinese and Polish language reports to decide if the trial fulfilled the inclusion criteria and where possible sought the help of translators.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-03 14:54:29 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Methods used to select trials for inclusion</HEADING>
<P>Two review authors (DB and IF) independently selected the trials to be included in the review. We resolved disagreements by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Criteria and methods used to assess the methodological quality of the included trials</HEADING>
<P>We extracted the following information from the included trials to assess methodological quality:<BR/>(1) method of randomisation and blinding;<BR/>(2) was CT performed?;<BR/>(3) total number of patients randomised and the proportion lost to follow up;<BR/>(4) was intention-to-treat analysis performed?<BR/>We attempted to obtain missing data by corresponding with trialists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methods used to collect data from the included trials</HEADING>
<P>Once we had reached agreement on which trials to include, one of the review authors (DB) extracted data from the trials and performed the data analysis. The other review author (IF) checked the accuracy of data extraction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methods used to synthesise the data</HEADING>
<P>We used the Peto method to give odds ratios. We planned to check for heterogeneity by using the I-squared test.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We planned the principal analysis for all routes and doses; a second analysis would separate trials using the oral route from those using the intravenous route. We planned a third analysis to separate studies by dose: we would analyse trials separately if a daily dose of at least 40 mg was given.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-03 14:54:54 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION>
<P>We excluded 16 studies from the review. We excluded three studies (<LINK REF="STD-Lipani-1984" TYPE="STUDY">Lipani 1984</LINK>; <LINK REF="STD-Manconi-1986" TYPE="STUDY">Manconi 1986</LINK>; <LINK REF="STD-Reneles-1986" TYPE="STUDY">Reneles 1986</LINK>) because the participants were not only stroke patients. <LINK REF="STD-Lipani-1984" TYPE="STUDY">Lipani 1984</LINK> had six stroke patients in the total group of 44, and some, if not all, of these six were in the chronic phase of stroke. <LINK REF="STD-Manconi-1986" TYPE="STUDY">Manconi 1986</LINK> had 40 participants in 13 diagnostic groups. Of these participants, 20 had ischaemic stroke, but the term 'previously established cerebral thrombosis' most probably denoted patients long after their stroke. At the end of the report 'chronic cerebral dysfunction' was mentioned referring to the whole study population and data were not presented separately for those with previous stroke. In <LINK REF="STD-Reneles-1986" TYPE="STUDY">Reneles 1986</LINK>, of the 49 participants enrolled, one died, one withdrew, and 17 were lost to follow up. The mean time from stroke onset to randomisation was 5.6 months. Of the 16 participants randomised within one month after stroke, no data were given for those randomised less than 14 days after stroke onset. </P>
<P>In one study (<LINK REF="STD-Levic-2001" TYPE="STUDY">Levic 2001</LINK>) the allocation of participants was unclear, the study was probably not randomised, it is not clear if treatment was started within two weeks of stroke onset, and the study evaluated the late neuropsychiatric consequences of stroke. Death and disability were not reported. One study (<LINK REF="STD-Wasilewski-1985" TYPE="STUDY">Wasilewski 1985</LINK>) had to be excluded because it was assumed that the vinpocetine arm of the study was not truly randomly selected; we attempted to clarify this with the principal investigator, but no source data could be obtained. One study (<LINK REF="STD-Atarashi-1983" TYPE="STUDY">Atarashi 1983</LINK>) excluded patients less than one month after stroke onset. Three studies had to be excluded because they were confounded: vinpocetine was compared to aminophylline (<LINK REF="STD-Domzal-1986" TYPE="STUDY">Domzal 1986</LINK>), to acupuncture (<LINK REF="STD-Zou-1990" TYPE="STUDY">Zou 1990</LINK>), or to another medication (venoruton) with unknown effect (<LINK REF="STD-Yi-2004" TYPE="STUDY">Yi 2004</LINK>). A Bulgarian study (<LINK REF="STD-Manchev-2003" TYPE="STUDY">Manchev 2003</LINK>) had to be excluded as it turned out to be non-randomised. A Russian study (<LINK REF="STD-Suslina-1999" TYPE="STUDY">Suslina 1999</LINK>) was excluded because it was not randomised and it reported only laboratory parameters and no clinical outcomes. A Czech study reported only CT findings, and probably was non-randomised (<LINK REF="STD-Kalvach-1988" TYPE="STUDY">Kalvach 1988</LINK>). Two Ukrainian studies had to be excluded as they turned out to be non-randomised studies (<LINK REF="STD-Dzyak-2002" TYPE="STUDY">Dzyak 2002</LINK>; <LINK REF="STD-Hadjiev-2004" TYPE="STUDY">Hadjiev 2004</LINK>). One study (<LINK REF="STD-Gliem-1988" TYPE="STUDY">Gliem 1988</LINK>) included 23 participants with acute stroke. In this double-blind study the method of allocation was not described and the study was excluded as no clinical outcomes were reported. In one study (<LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) only patients with cerebral haemorrhage were included. </P>
<P>Two studies fulfilled the selection criteria for inclusion in the review; that is, they were unconfounded randomised studies in acute ischaemic stroke (<LINK REF="STD-Werner-1986" TYPE="STUDY">Werner 1986</LINK>; <LINK REF="STD-Feigin-2001" TYPE="STUDY">Feigin 2001</LINK>). In <LINK REF="STD-Werner-1986" TYPE="STUDY">Werner 1986</LINK> 40 participants were randomised within 48 hours of stroke onset. The participants got either placebo or 40 mg of vinpocetine in a 200 ml dextran intravenous infusion for three weeks. Follow-up examinations were performed weekly for three weeks. Patient inclusion was restricted to those with relatively mild clinical signs (not requiring hospitalisation, but may be dependent on help of others). Dependent participants were defined as those who could not be discharged at the end of the trial into their own care or that of the family. In <LINK REF="STD-Feigin-2001" TYPE="STUDY">Feigin 2001</LINK> 30 participants were included within 72 hours of stroke onset, and all participants had a CT scan before inclusion. The participants got either low-molecular-weight dextran in 250 ml saline intravenously alone (in the control group) or in combination with 10 mg of vinpocetine for five to seven days followed by oral vinpocetine 10 mg three times a day. Follow up was performed at one and three months. Death, disability and dependency (the Barthel and the Rankin score), and the National Institutes of Health (NIH) scale score were the outcome measures at one and three months after stroke. Poor outcome was defined as being dead or having a Barthel index of less than 70 or a Rankin score of 3 to 5. There are no trials awaiting assessment and the review authors do not know of any ongoing trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>In the first randomised double-blind controlled unconfounded study of vinpocetine in acute stroke (<LINK REF="STD-Werner-1986" TYPE="STUDY">Werner 1986</LINK>) the method of randomisation was not reported, CT was either not performed or the results not reported, the follow up was short and there was no real measurement of dependency. Outcome measures in seven of 40 participants were not reported as the participants were excluded prior to analysis due to protocol violation (these participants got concomitant medication that was not allowed during the study), and no intention-to-treat analysis was performed. The second study (<LINK REF="STD-Feigin-2001" TYPE="STUDY">Feigin 2001</LINK>) was a single-blind randomised trial (participants were unaware of the treatment assignment). The method of randomisation is described, all participants had CT before randomisation, clinically relevant outcome measures were reported and no participants were lost to follow up. The treatment groups were comparable for major prognostic factors.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-03 14:54:54 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Death or dependency</HEADING>
<P>The primary outcome measure (death or dependency) was reported in both studies. We accepted the definitions and cut off values used in the studies when dichotomising the participants into dependent and independent. For early outcome (three to four weeks after stroke) data on 63 participants were available, and there was no significant difference between the treatment and the control groups if dependency was measured by the Rankin score (Peto odds ratio (OR) 0.44, 95% confidence interval (CI) 0.15 to 1.27) (Comparison 01.01) or disability/dependency by the Barthel score (Peto OR 0.52, 95% CI 0.11 to 2.54) (Comparison 01.02). Data on death or dependency at three months were available only in the study of <LINK REF="STD-Feigin-2001" TYPE="STUDY">Feigin 2001</LINK> for 30 participants, and there was no statistically significant difference between the treatment and control groups in the rate of death or dependency when dependency was measured by the Rankin score (Peto OR 0.34, 95% CI 0.06 to 1.79) (Comparison 01.04) or disability/dependency by the Barthel score (Peto OR 0.63, 95% CI 0.10 to 4.15) (Comparison 01.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death</HEADING>
<P>No participants died in the <LINK REF="STD-Werner-1986" TYPE="STUDY">Werner 1986</LINK> study, whereas two out of 15 treated participants and one out of 15 controls died in the <LINK REF="STD-Feigin-2001" TYPE="STUDY">Feigin 2001</LINK> study by the end of follow up. Two of these deaths occurred within the first month in the vinpocetine group, and the third death occurred in the control group between one and three months after stroke. There was no statistically significant difference between the groups, and the confidence intervals for the Peto odds ratio were wide: at one month Peto OR 7.94, 95% CI 0.47 to 133.26 (Comparison 01.03) and at three months Peto OR 2.05, 95% CI 0.20 to 21.36 (Comparison 01.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>As only two small studies were identified that fulfilled the inclusion criteria, we could not perform the planned sensitivity and subgroup analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety parameters</HEADING>
<P>No fatal or non-fatal cerebral haemorrhages, no cases of pulmonary embolism, and no other fatal or non-fatal adverse events occurred in either of the two studies.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Only two small trials fulfilled the inclusion criteria for this review. The total number of randomised participants was small. In one of the studies, data for almost 20% of randomised participants were lost and the follow up was short (<LINK REF="STD-Werner-1986" TYPE="STUDY">Werner 1986</LINK>). For the primary outcome measure (death or dependency) as well as for case fatality, the confidence intervals are wide, and include both the possibility of significant benefit and significant harm. Due to the lack of sufficient data, currently no conclusion can be drawn for the use of vinpocetine in acute stroke.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The two randomised, controlled, unconfounded studies of vinpocetine in acute ischaemic stroke had a small number of patients included. Presently there is not enough evidence to decide if the routine application of vinpocetine does or does not decrease case fatality and the proportion of dependent survivors in acute ischaemic stroke. Therefore, there is no evidence to support the routine administration of vinpocetine for all patients with acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>According to present standards of clinical research the clinical efficacy of vinpocetine in acute ischaemic stroke has not yet been properly evaluated. Based on in vitro studies and on animal experiments, as well as on human randomised studies, vinpocetine has effects that might be beneficial in acute stroke. To prove this hypothesis, placebo-controlled unconfounded properly randomised clinical studies must be designed and performed. In these studies much larger sample sizes, the registration of early and late case fatality and of valid and reliable measures of dependency and disability would be needed to estimate the risks and benefits of this agent. Brain CT or magnetic resonance imaging (MRI) should be part of the study protocol, long-term follow up (for example, three and six months) should be mandatory and intention-to-treat analysis should be performed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The infrastructure of the Department of Neurology, University Medical School of Debrecen supported the preparation of this review. The review authors thank the following manufacturers of vinpocetine for providing published and unpublished information for studies of vinpocetine: Gedeon Richter Ltd, Budapest, Hungary; Takeda Chemical Industries Ltd, Osaka, Japan; Covex SA, Madrid, Spain; and Thiemann Arzneimittel, Waltrop, Germany.</P>
<P>The authors also thank Gedeon Richter Ltd for providing English transcripts of papers originally published in Japanese, and for efforts to try to establish co-operation between the review authors and principal investigators of the studies. The help of Dr Bálint Ernyey in collecting papers in Russian not available in Hungary and the activity of Dr László Mihálka and Dr You Hong in evaluating the methods of the Russian, Ukrainian and Chinese language studies is also appreciated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>One of the review authors (DB) was supported by an unrestricted travel grant for a Cochrane training course, and both review authors participated in clinical studies sponsored by one of the manufacturers of vinpocetine (Gedeon Richter Ltd, Budapest, Hungary). The company did not have any influence on selection of subject, or on the design, conduct, analysis and reporting of this systematic review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr Istvan Fekete: participated in data collection for the review, screened retrieved papers against inclusion criteria, appraised the quality of papers, screened data for published and unpublished studies, interpreted the data, and provided general advice on the review.</P>
<P>Dr Daniel Bereczki: participated in all phases of the protocol and review preparation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Feigin-2001" NAME="Feigin 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV</AU>
<TI>Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial</TI>
<SO>European Journal of Neurology</SO>
<YR>2001</YR>
<VL>8</VL>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feigin VL</AU>
<TI>Safety and efficacy of Kavinton in the treatment of acute ischemic insult. A randomised clinical trial</TI>
<TO>Bezopasnost i effektivnost kavintona v lechenii ostrova ishemicheskovo insulta. Randomizirovannoe klinicheskoe issledovanie</TO>
<SO>Russki Medicinski Zhurnal</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>15-16</NO>
<PG>638-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Werner-1986" NAME="Werner 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Werner J, Apececha M, Schaltenbrand R, Fenzl E</AU>
<TI>Clinical study to evaluate the efficacy and tolerance of vinpocetine i.v. added to standard therapy in patients suffering from an acute apoplectic insult</TI>
<SO>Senile Dementias: Early Detection</SO>
<YR>1986</YR>
<PG>636-41</PG>
<ED>Bés A</ED>
<PB>John Libbey Eurotext</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Werner J</AU>
<TI>Final medical report on the testing of the efficacy and tolerance of vinpocetine after the intravenous application to outpatients suffering from apoplectic attack</TI>
<SO>RGD document numbers 36350/E; 34885/G</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Werner JP, Lohaus R</AU>
<TI>Statistical evaluation of the tests of the efficacy and tolerance of the intravenous administration of vinpocetine as an additional therapy in the case of outpatients with an apoplectic shock in the context of a controlled double-blind study</TI>
<SO>Thiemann Arzneimittel, Test No. 045.290</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Atarashi-1983" NAME="Atarashi 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atarashi J, Araki G, Ito E, Otomo E, Omae T, Kuzuya F, et al</AU>
<TI>Usefulness of TCV-3B tablets in the treatment of patients with cerebrovascular disorders - a multicenter double-blind clinical evaluation using ifenprodil tartarate tablets as control</TI>
<SO>Igakumo Ayumi</SO>
<YR>1983</YR>
<VL>124</VL>
<PG>66-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Domzal-1986" NAME="Domzal 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Domzal T, Kozlowski P, Zaleska B</AU>
<TI>Cavinton in the treatment of ischaemic brain stroke. Clinical and computer-tomographic evaluation</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>1986</YR>
<VL>20</VL>
<NO>36</NO>
<PG>234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dzyak-2002" NAME="Dzyak 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dzyak LA, Golik VA, Rozhkova IV, Mizyakina EV</AU>
<TI>Efficacy of Cavinton in the treatment of cerebral ischemias, caused by the pathology of main arteries of the head</TI>
<SO>Ukrainskij Medichnij Chasopis</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>32</NO>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gliem-1988" NAME="Gliem 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gliem S, Mielke U</AU>
<TI>Rheoencephalographic examination of patients with acute stroke receiving Cavinton</TI>
<TO>Rheoenzephalographische untersuchungen bei patienten mit akutem zerebraleninsult unter Cavinton</TO>
<SO>Zeitshrift für Klinische Medizin</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>8</NO>
<PG>653-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hadjiev-2004" NAME="Hadjiev 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hadjiev D</AU>
<TI>Latent insufficiency of cerebral blood circulation and neuroprotective therapy as a primary prevention of ischemic stroke</TI>
<SO>Ukrainski Medichni Chasopis</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>43</NO>
<PG>47-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalvach-1988" NAME="Kalvach 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalvach P, Bauer J, Vymazal J</AU>
<TI>Computed tomography study of cerebral infarctions treated with vinpocetine</TI>
<SO>Drug Development Research</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>3-4</NO>
<PG>227-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levic-2001" NAME="Levic 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levic Z, Ziklic M, Ocic GG, Diklic-Jeremic VV, Dujmovic I</AU>
<TI>Efficacy and safety of Cavinton in the treatment of cerebrovascular diseases</TI>
<TO>Efikasnost i bezbednost Cavintona u tretiranju cerebrovaskularnih bolesti</TO>
<SO>Aktuelnosti iz Neurologije, Psihijatrije i Granicnih Podrucja</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>1-2</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Lipani-1984" NAME="Lipani 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Lipani G</AU>
<TI>A double-blind parallel group placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction</TI>
<SO>Garibaldi Provincial General Hospital, Catania, Italy: Protocol 84-175,</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Lipani G</AU>
<TI>Clinical/experimental evaluations of the therapeutic efficacy and tolerability of the medical preparation "Cavinton" of Ayerst Italiana S.p.A</TI>
<SO>Ayerst Report AX-27, 255-35,</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manchev-2003" NAME="Manchev 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manchev I, Tsolova M, Mancheva V</AU>
<TI>Cavinton (vinpocetine) treatment in acute ischaemic cerebrovascular disorders</TI>
<TO>Lechenie s kavinton (vinpocetine) pri ostri ischemichni narushenia na mozhchnot krovoobrashenie</TO>
<SO>Bulgarian Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manconi-1986" NAME="Manconi 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manconi E, Binaghi F, Pitzus F</AU>
<TI>A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin</TI>
<SO>Current Therapeutic Research</SO>
<YR>1986</YR>
<VL>40</VL>
<PG>702-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Reneles-1986" NAME="Reneles 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Reneles LD, Villadolid L, Florete OG</AU>
<TI>Cavinton in the treatment of thrombotic strokes</TI>
<SO>Ayerst International Central file #AX/27, 255/128,</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suslina-1999" NAME="Suslina 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suslina ZA, Fedorova TN, Kistenev BA, Khrapova EV, Maksimova MY</AU>
<TI>Dynamics of lipid peroxidation in patients with acute ischemic stroke</TI>
<SO>Zhurnal Nevrologii i Psichiatrii</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" NAME="Wang 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Li J, Zhang Y</AU>
<TI>A clinical observation of efficacy of vinpocetine injection on acute cerebral hemorrhage</TI>
<SO>Progress in Pharmaceutical Sciences</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>12</NO>
<PG>563-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wasilewski-1985" NAME="Wasilewski 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Wasilewski R. Effect of Cavinton treatment on the dynamics of the clinical syndromes of acute and chronic cerebral vascular disturbances. 1985.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Wasilewski R</AU>
<TI>Effect of Cavinton treatment on the dynamics of the clinical syndromes of acute and chronic cerebral vascular disturbances</TI>
<SO>Richter Gedeon document number: 32140,</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2004" NAME="Yi 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yi YX, Yang Y, Qu XB, Liu YL</AU>
<TI>Effect of vinpocetine on hemodynamics and neurologic impairment in senile patients with acute cerebral infarction</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2004</YR>
<VL>8</VL>
<NO>28</NO>
<PG>6122-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zou-1990" NAME="Zou 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zou X, Wang D</AU>
<TI>Comparative study of cerebral infarction treated with acupuncture at 6 acupoints of yang meridian and calan</TI>
<SO>Chung Hsi I Chieh Ho Tsa Chih</SO>
<YR>1990</YR>
<VL>10</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Adams-2007" NAME="Adams 2007" TYPE="JOURNAL_ARTICLE">
<AU>Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al</AU>
<TI>Guidelines for early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>1655-711</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APT-1994" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists' Collaboration</AU>
<TI>Collaborative overview of randomized trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Backhauss-1992" NAME="Backhauss 1992" TYPE="JOURNAL_ARTICLE">
<AU>Backhauss C, Karkoutly C, Welsch M, Krieglstein J</AU>
<TI>A mouse model of focal cerebral ischemia for screening neuroprotective drug effects</TI>
<SO>Journal of Pharmacological Methods</SO>
<YR>1992</YR>
<VL>27</VL>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balestreri-1987" NAME="Balestreri 1987" TYPE="JOURNAL_ARTICLE">
<AU>Balestreri R, Fontana L, Astengo F</AU>
<TI>A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonita-1990" NAME="Bonita 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bonita R, Stewart A, Beaglehole R</AU>
<TI>International trends in stroke mortality: 1970-1985</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>989-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonita-1992" NAME="Bonita 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bonita R</AU>
<TI>Epidemiology of stroke</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<PG>342-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broderick-2002" NAME="Broderick 2002" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Hacke W</AU>
<TI>Treatment of acute ischemic stroke. Part II: Neuroprotection and medical management</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>106</VL>
<PG>1736-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f6_n_x00f6_czk-2000" NAME="Bönöczk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bönöczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E, Kiss B, et al</AU>
<TI>Role of sodium channel inhibition in neuroprotection: effect of vinpocetine</TI>
<SO>Brain Research Bulletin</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>3</NO>
<PG>245-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f6_n_x00f6_czk-2002" NAME="Bönöczk 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bönöczk P, Panczel G, Nagy Z</AU>
<TI>Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study</TI>
<SO>European Journal of Ultrasound</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erd_x00f6_-1990" NAME="Erdö 1990" TYPE="JOURNAL_ARTICLE">
<AU>Erdö SL, Ning-Sheng C, Wolff JR, Kiss B</AU>
<TI>Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1990</YR>
<VL>187</VL>
<PG>551-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EUSI-2003" NAME="EUSI 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Kaste M, Bogusslavsky J, Brainin M, Chamorro A, Lees K et al</AU>
<TI>European Stroke Initiative recommendations for stroke management - update 2003</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>4</NO>
<PG>311-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabryel-2002" NAME="Gabryel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gabryel B, Adamek M, Pudelko A, Malecki A, Trzeciak HI</AU>
<TI>Piracetam and vinpocetin exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation</TI>
<SO>Neurotoxicology</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>19-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulyas-2002a" NAME="Gulyas 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Gulyas B, Halldin C, Sandell J, Karlsson P, Sovago J, Karpati E, et al</AU>
<TI>PET studies on the brain uptake and regional distribution of 11C-vinpocetine in human subjects</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2002</YR>
<VL>106</VL>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulyas-2002b" NAME="Gulyas 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Gulyas B, Halldin C, Sovago J, Sandell J, Cselenyi Z, Vas A, et al</AU>
<TI>Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroptrotective drug vinpocetine</TI>
<SO>European Journal of Nuclear Medicine and Molecular Imaging</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>1031-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayakawa-1992" NAME="Hayakawa 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hayakawa M</AU>
<TI>Effect of vinpocetine on red blood cell deformability in stroke patients</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1992</YR>
<VL>42</VL>
<PG>425-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horvath-2002" NAME="Horvath 2002" TYPE="JOURNAL_ARTICLE">
<AU>Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, et al</AU>
<TI>In vitro antioxidant properties of pentoxifylline, piracetam and vinpocetine</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Itoh-1982" NAME="Itoh 1982" TYPE="JOURNAL_ARTICLE">
<AU>Itoh T</AU>
<TI>Effect of vinpocetine on platelet aggregation in patients with cerebrovascular diseases</TI>
<SO>Japanese Pharmacology and Therapeutics</SO>
<YR>1982</YR>
<VL>10</VL>
<PG>1481-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemeny-2005" NAME="Kemeny 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kemeny V, Molnar S, Andrejkovics M, Makai A, Csiba L</AU>
<TI>Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>1048-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kesteloot-2006" NAME="Kesteloot 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kesteloot H, Sans S, Kromhout D</AU>
<TI>Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiss-1991" NAME="Kiss 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kiss B, Ning-Sheng C, Erdo SL</AU>
<TI>Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1991</YR>
<VL>209</VL>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kov_x00e1_cs-1985" NAME="Kovács 1985" TYPE="JOURNAL_ARTICLE">
<AU>Kovács L</AU>
<TI>Cavinton in the treatment of acute stroke</TI>
<SO>Therapia Hungarica</SO>
<YR>1985</YR>
<VL>33</VL>
<PG>50-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krieglstein-1991" NAME="Krieglstein 1991" TYPE="JOURNAL_ARTICLE">
<AU>Krieglstein J, Rischke R</AU>
<TI>Vinpocetine increases the neuroprotective effect of adenosine in vitro</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1991</YR>
<VL>205</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lakics-1995" NAME="Lakics 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lakics V, Sebestyen MG, Erdo SL</AU>
<TI>Vinpocetine is a highly potent neuroprotectant against veratradine induced cell death in primary cultures of rat cerebral cortex</TI>
<SO>Neuroscience Letters</SO>
<YR>1995</YR>
<VL>185</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lamar-1988" NAME="Lamar 1988" TYPE="JOURNAL_ARTICLE">
<AU>Lamar J-C, Poignet H, Beaughard M, Dureng G</AU>
<TI>Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischaemia</TI>
<SO>Drug Development Research</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medina-2006" NAME="Medina 2006" TYPE="JOURNAL_ARTICLE">
<AU>Medina AE, Krahe TE, Ramoa AS</AU>
<TI>Restoration of neuronal plasticity by a phosphodiesterase type 2 inhibitor in a model of fetal alcohol exposure</TI>
<SO>Journal of Neuroscience</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>1057-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendoza-2007" NAME="Mendoza 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mendoza G, Alvarez AI, Pulido MM, Molna AJ, Merino G, Real R, et al</AU>
<TI>Inhibitory effects of different antioxidants on hyaluronan depolymerization</TI>
<SO>Carbohydrate Research</SO>
<YR>2007</YR>
<VL>342</VL>
<PG>96-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moln_x00e1_r-1995" NAME="Molnár 1995" TYPE="JOURNAL_ARTICLE">
<AU>Molnár P, Erdo SL</AU>
<TI>Vinpocetine is as potent as phenytoin to block voltage-gated Na channels in rat cortical neurons</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1995" NAME="Moore 1995" TYPE="JOURNAL_ARTICLE">
<AU>Moore WS, Barnett HJM, Beebe HG, Bernstein EF, Brener BJ, Brott T, et al</AU>
<TI>Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<PG>188-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Collins-2006" NAME="O'Collins 2006" TYPE="JOURNAL_ARTICLE">
<AU>O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW</AU>
<TI>1026 experimental treatments in acute stroke</TI>
<SO>Annals of Neurology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>467-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-2000" NAME="Pereira 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pereira C, Agostinho P, Oliveira CR</AU>
<TI>Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells</TI>
<SO>Free Radical Research</SO>
<YR>2000</YR>
<VL>33</VL>
<PG>497-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rischke-1990a" NAME="Rischke 1990a" TYPE="BOOK_SECTION">
<AU>Rischke R, Krieglstein J</AU>
<TI>Protective effects of vinpocetine against brain damage caused by focal or global cerebral ischemia</TI>
<SO>Pharmacology of Cerebral Ischemia</SO>
<YR>1990</YR>
<PG>527-32</PG>
<ED>Krieglstein J, Oberpichler H</ED>
<PB>Wissenschaftliche Verlagsgesellschaft</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rischke-1990b" NAME="Rischke 1990b" TYPE="JOURNAL_ARTICLE">
<AU>Rischke R, Krieglstein J</AU>
<TI>Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischaemia in the rat</TI>
<SO>Pharmacology</SO>
<YR>1990</YR>
<VL>41</VL>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-2002" NAME="Rose 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rose SPR</AU>
<TI>'Smart drugs': Do they work? Are they ethical? Will they be legal?</TI>
<SO>Nature Reviews Neuroscience</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>12</NO>
<PG>975-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sacco-2006" NAME="Sacco 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al</AU>
<TI>Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>e409-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-2003" NAME="Sandercock 2003" TYPE="COCHRANE_REVIEW">
<AU>Sandercock P, Gubitz G, Foley P, Counsell C</AU>
<TI>Antiplatelet therapy for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000029. DOI: 10.1002/14651858. CD000029"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Santos-2000" NAME="Santos 2000" TYPE="JOURNAL_ARTICLE">
<AU>Santos MS, Duarte AI, Moreira PI, Oliveira CR</AU>
<TI>Synaptosomal response to oxidative stress: effect of vinpocetine</TI>
<SO>Free Radical Research</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>1</NO>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sauer-1988" NAME="Sauer 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sauer D, Rischke R, Beck T, Rossberg C, Mennel H-D, Bielenberg GW, et al</AU>
<TI>Vinpocetine prevents ischemic cell damage in rat hippocampus</TI>
<SO>Life Sciences</SO>
<YR>1988</YR>
<VL>43</VL>
<PG>1733-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sitges-2007" NAME="Sitges 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sitges M, Chiu LM, Guarneros, Nekrassov V</AU>
<TI>Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na(+) channel-mediated release of 3H-glutamate in hippocampal nerve endings</TI>
<SO>Neuropharmacology</SO>
<YR>2007</YR>
<VL>52</VL>
<PG>598-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Szakall-1998" NAME="Szakall 1998" TYPE="JOURNAL_ARTICLE">
<AU>Szakall S, Boros I, Balkay L, Emri M, Fekete I, Kerenyi L, et al</AU>
<TI>Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study</TI>
<SO>Journal of Neuroimaging</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>4</NO>
<PG>197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Szilagyi-2005" NAME="Szilagyi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Szilagyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, et al</AU>
<TI>Effects of vinpocetine on redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2005</YR>
<VL>229-30</VL>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tamaki-1985" NAME="Tamaki 1985" TYPE="JOURNAL_ARTICLE">
<AU>Tamaki N, Kusunoki T, Matsumoto S</AU>
<TI>The effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disorders</TI>
<SO>Therapia Hungarica</SO>
<YR>1985</YR>
<VL>33</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tretter-1998" NAME="Tretter 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tretter L, Adam-Vizi V</AU>
<TI>The neuroprotective drug vinpocetine prevents veratridine-induced Na+i and Ca2+i rise in synaptosomes</TI>
<SO>Neuroreport</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1849-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2003" NAME="Wardlaw 2003" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, Zoppo G, Yamaguchi T, Berge E</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000213. DOI: 10.1002/14651858. CD000213"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zelles-2001" NAME="Zelles 2001" TYPE="JOURNAL_ARTICLE">
<AU>Zelles T, Franklin L, Koncz I, Lendvai B, Zsilla G</AU>
<TI>The nootropic drug vinpocetine inhibits veratradine-induced Ca2+i increase in rat hippocampal CA1 pyramidal cells</TI>
<SO>Neurochemical Research</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>1095-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2003" NAME="Zhou 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zhou G, Dong XW, Crona J, Maguire M, Priestley T</AU>
<TI>Vinpocetine is a potent blocker of rat NaV 1.8 tetrodotoxin resistant sodium channels</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2003</YR>
<VL>306</VL>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Bereczki-1997" NAME="Bereczki 1997" TYPE="COCHRANE_REVIEW">
<AU>Bereczki D, Fekete I</AU>
<TI>Vinpocetine for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000480. DOI: 10.1002/14651858. CD000480"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bereczki-1999" NAME="Bereczki 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bereczki D, Fekete I</AU>
<TI>A systematic review of vinpocetine therapy in acute ischaemic stroke</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1999</YR>
<VL>55</VL>
<NO>5</NO>
<PG>349-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Feigin-2001">
<CHAR_METHODS>
<P>Computer generated randomisation codes, sequentially numbered opaque sealed envelopes<BR/>No participants lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients within 72 hours of CT-verified acute ischaemic stroke</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Low-molecular-weight dextran alone (3 g in 250 ml of isotonic saline) in the control group, or in combination with 10 mg iv vinpocetine for 5 to 7 days, followed by oral vinpocetine 3 x 10 mg in the treatment group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glasgow Coma Scale, NIH Stroke Scale, Barthel and Rankin scores at 1 and 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Werner-1986">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled<BR/>Method of randomisation not stated<BR/>CT either not performed or not reported<BR/>7 out of 40 patients dropped from analysis after randomisation (protocol violators)<BR/>Intention-to-treat analysis not performed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients of either sex, no more than 48 hours after stroke onset, relatively mild clinical signs (no need for hospitalisation)<BR/>The study was performed in Germany, the mean age of participants was 67.7 years (range: 48 to 82 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vinpocetine 40 mg or placebo in 200 ml dextran iv infusion over one hour daily for 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dependency on other than self or family, cognitive functions on mini mental state examination, self assessment by visual analogue scale, clinical global impression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Independence defined as 'dischargable into their own care or that of the family' or 'able to live relatively independently in their home environments'<BR/>No deaths within 3 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CT: computerised tomography<BR/>iv: intravenous<BR/>NIH: National Institutes of Health</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Atarashi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients with stroke within one month were excluded from the study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Domzal-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded study: vinpocetine (27 participants) was compared with aminophylline (30 participants)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dzyak-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gliem-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>The method of allocation was not described<BR/>No clinical outcomes were reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hadjiev-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalvach-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported, and probably a non-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levic-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study was probably not randomised, it is not clear if treatment was started within 2 weeks of stroke onset, and the study evaluated the late neuropsychiatric consequences of stroke<BR/>Death and disability are not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipani-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>In addition to stroke patients, patients with other diagnostic categories (TIA, dementia, Huntington's chorea) also entered the study<BR/>The number of participants with stroke was small (6 participants), and some, if not all, of these were in the chronic phase of stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manchev-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>253 patients treated with 10 to 20 mg vinpocetine for 5 to 30 days iv or 3 to 30 days per os and 40 controls<BR/>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manconi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients with diagnostic categories other than stroke also entered the study<BR/>The term 'previously established cerebral thrombosis' most probably denoted patients a long time after stroke and not patients with acute stroke<BR/>At the end of the report &#8216;chronic cerebral dysfunction&#8217; is mentioned referring to the whole study population and data are not presented separately for those with previous stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reneles-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed patient group (TIA, acute and chronic stroke)<BR/>The mean time from stroke onset to randomisation was 5.6 months<BR/>Of the 16 participants randomised within one month after stroke no data were given for those randomised less than 14 days after stroke onset<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Suslina-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study<BR/>Lipid peroxidation was measured<BR/>No clinical outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study performed in acute hemorrhagic stroke<BR/>Patients with ischaemic stroke were excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wasilewski-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>There were 50 participants in both the placebo and cinnarizine groups whereas in the vinpocetine group there were only 32<BR/>This imbalance in sample size plus the term 'the patient groups were selected at random' suggests that randomisation, if performed at all, was improper<BR/>We attempted to clarify this with the principal investigator, but no source data could be obtained</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yi-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>83 patients were screened, 70 were randomised: 35 to vinpocetine and 35 to venoruton<BR/>Therefore the study is confounded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zou-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Based on the MEDLINE abstract the study was confounded because vinpocetine was compared with acupuncture</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>iv: intravenous<BR/>per os: by mouth<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Feigin-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Werner-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Vinpocetine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.49453212297960136" CI_END="1.2712491721475816" CI_START="0.15251587787420418" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.44032452065146643" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.10423068311321658" LOG_CI_START="-0.8166849411421329" LOG_EFFECT_SIZE="-0.3562271290144582" METHOD="PETO" NO="1" P_CHI2="0.48191261256227025" P_Q="1.0" P_Z="0.1294434223730986" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.516300353246799">
<NAME>Death or dependency at one month: Rankin</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6818300186688333" CI_START="0.1321382163485808" EFFECT_SIZE="0.6975030118684518" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5660637342879802" LOG_CI_START="-0.878971559758646" LOG_EFFECT_SIZE="-0.156453912735333" ORDER="54341" O_E="-0.5" SE="0.8488208847630565" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="40.61465545798017"/>
<DICH_DATA CI_END="1.2725107484454645" CI_START="0.08121338755470661" EFFECT_SIZE="0.3214730293213278" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.10466145935523234" LOG_CI_START="-1.0903723739374547" LOG_EFFECT_SIZE="-0.49285545729111113" ORDER="54342" O_E="-2.3030303030303028" SE="0.7019687891890032" STUDY_ID="STD-Werner-1986" TOTAL_1="17" TOTAL_2="16" VAR="2.0293847566574836" WEIGHT="59.38534454201984"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5398229353425337" CI_START="0.10537011876084396" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5173214129809031" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4048034406813128" LOG_CI_START="-0.9772825304628721" LOG_EFFECT_SIZE="-0.2862395448907797" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.4168810776174644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.8118441408859889">
<NAME>Death or dependency at one month: Barthel</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.539822935342534" CI_START="0.10537011876084396" EFFECT_SIZE="0.5173214129809031" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.40480344068131285" LOG_CI_START="-0.9772825304628721" LOG_EFFECT_SIZE="-0.2862395448907797" ORDER="54343" O_E="-1.0" SE="0.8118441408859888" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.5172413793103448" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="133.25952883863062" CI_START="0.47263047688345405" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.32547827695766934" LOG_EFFECT_SIZE="0.8996099982281647" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.1500808834687166" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.4392458342578487">
<NAME>Death at one month</NAME>
<GROUP_LABEL_1>Vinpocetine 40 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="133.25952883863062" CI_START="0.4726304768834543" EFFECT_SIZE="7.936152384138449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1246982734139985" LOG_CI_START="-0.3254782769576691" LOG_EFFECT_SIZE="0.8996099982281647" ORDER="54344" O_E="1.0" SE="1.439245834257849" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.48275862068965514" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54345" O_E="0.0" SE="0.0" STUDY_ID="STD-Werner-1986" TOTAL_1="17" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7912487849702143" CI_START="0.06428662330481592" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3393425052724598" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2531559088173142" LOG_CI_START="-1.1918793852293121" LOG_EFFECT_SIZE="-0.46936173820599886" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.20293599261359885" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.2732313271445845">
<NAME>Death or dependency at three months: Rankin</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7912487849702143" CI_START="0.06428662330481592" EFFECT_SIZE="0.3393425052724598" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2531559088173142" LOG_CI_START="-1.1918793852293121" LOG_EFFECT_SIZE="-0.46936173820599886" ORDER="54346" O_E="-1.5" SE="0.8488208847630565" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.154064843678989" CI_START="0.09517030241539737" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6287635544670984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6184732714557427" LOG_CI_START="-1.0214985506619605" LOG_EFFECT_SIZE="-0.20151263960310883" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.630044809467624" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4816637831516918">
<NAME>Death or dependency at three months: Barthel</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.154064843678988" CI_START="0.09517030241539741" EFFECT_SIZE="0.6287635544670984" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6184732714557426" LOG_CI_START="-1.0214985506619603" LOG_EFFECT_SIZE="-0.20151263960310883" ORDER="54347" O_E="-0.5" SE="0.9633275663033836" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="1.0775862068965518" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.36052798587458" CI_START="0.196038155693089" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5496053262803492" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.5983516452371671">
<NAME>Death at three months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.36052798587458" CI_START="0.196038155693089" EFFECT_SIZE="2.0463329423584677" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3296119833058593" LOG_CI_START="-0.7076593919382393" LOG_EFFECT_SIZE="0.3109762956838099" ORDER="54348" O_E="0.5" SE="1.1967032904743342" STUDY_ID="STD-Feigin-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>